Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Maggie Li; Evan J. Beck; Oliver Laeyendecker; Yolanda Eby; Aaron A.R. Tobian; Patrizio Caturegli; Camille Wouters; Gregory R. Chiklis; William Block; Robert O. McKie; Michael J. Joyner; Timothy D. Wiltshire; Allan B. Dietz; Thomas J. Gniadek; Arell J. Shapiro; Anusha Yarava; Karen Lane; Daniel F. Hanley; Evan M. Bloch; Shmuel Shoham; Edward R. Cachay; Barry R. Meisenberg; Moises A. Huaman; Yuriko Fukuta; Bela Patel; Sonya L. Heath; Adam C. Levine; James H. Paxton; Shweta Anjan; Jonathan M. Gerber; Kelly A. Gebo; Arturo Casadevall; Andrew Pekosz; David J. Sullivan

doi:10.1182/bloodadvances.2022007410

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Maggie Li, Evan J. Beck, Oliver Laeyendecker, Yolanda Eby, Aaron A.R. Tobian, Patrizio Caturegli, Camille Wouters, Gregory R. Chiklis, William Block, Robert O. McKie, Michael J. Joyner, Timothy D. Wiltshire, Allan B. Dietz, Thomas J. Gniadek, Arell J. Shapiro, Anusha Yarava, Karen Lane, Daniel F. Hanley, Evan M. Bloch, Shmuel ShohamEdward R. Cachay, Barry R. Meisenberg, Moises A. Huaman, Yuriko Fukuta, Bela Patel, Sonya L. Heath, Adam C. Levine, James H. Paxton, Shweta Anjan, Jonathan M. Gerber, Kelly A. Gebo, Arturo Casadevall, Andrew Pekosz, David J. Sullivan

Research output: Contribution to journal › Article › peer-review

Abstract

The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.

Original language	English (US)
Pages (from-to)	3678-3683
Number of pages	6
Journal	Blood Advances
Volume	6
Issue number	12
DOIs	https://doi.org/10.1182/bloodadvances.2022007410
State	Published - Jun 28 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1182/bloodadvances.2022007410

Cite this

Li, M., Beck, E. J., Laeyendecker, O., Eby, Y., Tobian, A. A. R., Caturegli, P., Wouters, C., Chiklis, G. R., Block, W., McKie, R. O., Joyner, M. J., Wiltshire, T. D., Dietz, A. B., Gniadek, T. J., Shapiro, A. J., Yarava, A., Lane, K., Hanley, D. F., Bloch, E. M., ... Sullivan, D. J. (2022). Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Advances, 6(12), 3678-3683. https://doi.org/10.1182/bloodadvances.2022007410

Li, M, Beck, EJ, Laeyendecker, O, Eby, Y, Tobian, AAR , Caturegli, P, Wouters, C, Chiklis, GR, Block, W, McKie, RO, Joyner, MJ, Wiltshire, TD, Dietz, AB, Gniadek, TJ, Shapiro, AJ, Yarava, A, Lane, K , Hanley, DF , Bloch, EM , Shoham, S, Cachay, ER, Meisenberg, BR, Huaman, MA, Fukuta, Y, Patel, B, Heath, SL, Levine, AC, Paxton, JH, Anjan, S, Gerber, JM, Gebo, KA , Casadevall, A , Pekosz, A & Sullivan, DJ 2022, 'Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern', Blood Advances, vol. 6, no. 12, pp. 3678-3683. https://doi.org/10.1182/bloodadvances.2022007410

@article{6b0800ba3b994aa88a28ac0798c5cd96,

title = "Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern",

abstract = "The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.",

author = "Maggie Li and Beck, {Evan J.} and Oliver Laeyendecker and Yolanda Eby and Tobian, {Aaron A.R.} and Patrizio Caturegli and Camille Wouters and Chiklis, {Gregory R.} and William Block and McKie, {Robert O.} and Joyner, {Michael J.} and Wiltshire, {Timothy D.} and Dietz, {Allan B.} and Gniadek, {Thomas J.} and Shapiro, {Arell J.} and Anusha Yarava and Karen Lane and Hanley, {Daniel F.} and Bloch, {Evan M.} and Shmuel Shoham and Cachay, {Edward R.} and Meisenberg, {Barry R.} and Huaman, {Moises A.} and Yuriko Fukuta and Bela Patel and Heath, {Sonya L.} and Levine, {Adam C.} and Paxton, {James H.} and Shweta Anjan and Gerber, {Jonathan M.} and Gebo, {Kelly A.} and Arturo Casadevall and Andrew Pekosz and Sullivan, {David J.}",

year = "2022",

month = jun,

day = "28",

doi = "10.1182/bloodadvances.2022007410",

language = "English (US)",

volume = "6",

pages = "3678--3683",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "12",

}

TY - JOUR

T1 - Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

AU - Li, Maggie

AU - Beck, Evan J.

AU - Laeyendecker, Oliver

AU - Eby, Yolanda

AU - Tobian, Aaron A.R.

AU - Caturegli, Patrizio

AU - Wouters, Camille

AU - Chiklis, Gregory R.

AU - Block, William

AU - McKie, Robert O.

AU - Joyner, Michael J.

AU - Wiltshire, Timothy D.

AU - Dietz, Allan B.

AU - Gniadek, Thomas J.

AU - Shapiro, Arell J.

AU - Yarava, Anusha

AU - Lane, Karen

AU - Hanley, Daniel F.

AU - Bloch, Evan M.

AU - Shoham, Shmuel

AU - Cachay, Edward R.

AU - Meisenberg, Barry R.

AU - Huaman, Moises A.

AU - Fukuta, Yuriko

AU - Patel, Bela

AU - Heath, Sonya L.

AU - Levine, Adam C.

AU - Paxton, James H.

AU - Anjan, Shweta

AU - Gerber, Jonathan M.

AU - Gebo, Kelly A.

AU - Casadevall, Arturo

AU - Pekosz, Andrew

AU - Sullivan, David J.

PY - 2022/6/28

Y1 - 2022/6/28

N2 - The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.

AB - The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants severely limits available effective monoclonal antibody therapies. Effective drugs are also supply limited. COVID-19 convalescent plasma (CCP) qualified for high antibody levels effectively reduces immunocompetent outpatient hospitalization. The Food and Drug Administration currently allows outpatient CCP for the immunosuppressed. Viral-specific antibody levels in CCP can range 10- to 100-fold between donors, unlike the uniform viral-specific monoclonal antibody dosing. Limited data are available on the efficacy of polyclonal CCP to neutralize variants. We examined 108 pre-d/pre-o donor units obtained before March 2021, 20 post-d COVID-19/postvaccination units, and 1 pre-d/pre-o hyperimmunoglobulin preparation for variant-specific virus (vaccine-related isolate [WA-1], d, and o) neutralization correlated to Euroimmun S1 immunoglobulin G antibody levels. We observed a two- to fourfold and 20- to 40-fold drop in virus neutralization from SARS-CoV-2 WA-1 to d or o, respectively.

UR - http://www.scopus.com/inward/record.url?scp=85133003551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133003551&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2022007410

DO - 10.1182/bloodadvances.2022007410

M3 - Article

C2 - 35443020

AN - SCOPUS:85133003551

SN - 2473-9529

VL - 6

SP - 3678

EP - 3683

JO - Blood Advances

JF - Blood Advances

IS - 12

ER -

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this